logo
Share SHARE
FONT-SIZE Plus   Neg

FT: Blackstone To Take Control Of SocGen Property Loans

Private equity giant Blackstone Group, LP (BX) is set to take control of commercial property loans worth 100 million euros owned by French lender Societe Generale SA (SCGLY.PK,SCGLF.PK), the Financial Times reported Sunday.

According to the FT report, the deal is likely to close within weeks and would perhaps be the most significant sale by Societe Generale as it works to reduce its exposure to real estate.

Societe Generale, like its peers across Europe, is trying to reduce its exposure to the real estate sector.

In mid-February, Societe Generale reported an 89 percent plunge in profit for the fourth quarter, weighed down by losses from its investment banking business. During the quarter, the company reduced its sovereign debt exposure to Greece, Italy, Ireland, Portugal and Spain - collectively called GIIPS countries - by nearly two-thirds.

On the other hand, Blackstone is seeking to grow its real estate business. In December 2011 Royal Bank of Scotland Group plc (RBS.L, RBS) signed a deal with Blackstone to manage a fund of 1.4 billion pounds of commercial real estate loans.

SCGLY.PK closed Friday's trading at $6.58, up $0.19 or 2.97 percent on a volume of 114,681 shares. BX closed trading at $15.30, down $0.04 or 0.26 percent on a volume of 4.08 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects. Alcobra Ltd.'s Investigational New Drug Applications for drug candidate MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome have been put on full clinical hold, following adverse neurological findings in a pre-clinical study.
comments powered by Disqus
Follow RTT